Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ROMIDEPSIN for Allogenic stem cell transplantation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 9 adverse event reports in the FDA FAERS database where ROMIDEPSIN was used for Allogenic stem cell transplantation.

Most Reported Side Effects for ROMIDEPSIN

Side Effect Reports % Deaths Hosp.
Peripheral t-cell lymphoma unspecified 102 8.0% 73 18
Nausea 91 7.1% 11 33
Death 90 7.0% 90 10
Thrombocytopenia 90 7.0% 23 29
Pyrexia 77 6.0% 18 49
Drug ineffective 69 5.4% 19 25
Anaemia 61 4.8% 14 21
Electrocardiogram qt prolonged 61 4.8% 5 3
Platelet count decreased 60 4.7% 22 24
Vomiting 57 4.5% 5 28
Fatigue 55 4.3% 7 21
Product storage error 53 4.1% 0 0
Atrial fibrillation 52 4.1% 9 23
Neutropenia 49 3.8% 9 10
Malignant neoplasm progression 45 3.5% 17 8

Other Indications for ROMIDEPSIN

Peripheral t-cell lymphoma unspecified (390) Product used for unknown indication (171) Angioimmunoblastic t-cell lymphoma (140) Cutaneous t-cell lymphoma (101) T-cell lymphoma (81) Mycosis fungoides (48) Breast cancer metastatic (37) Lymphoma (30) Acute myeloid leukaemia (29) Adult t-cell lymphoma/leukaemia (20)

Other Drugs Used for Allogenic stem cell transplantation

FLUDARABINE (2,008) BUSULFAN (1,624) THIOTEPA (1,476) CYCLOPHOSPHAMIDE (701) CYCLOSPORINE (556) LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN (539) MYCOPHENOLATE MOFETIL (428) TREOSULFAN (397) MELPHALAN (374) TACROLIMUS (326)

Related Pages

ROMIDEPSIN Full Profile All Allogenic stem cell transplantation Drugs ROMIDEPSIN Demographics ROMIDEPSIN Timeline